{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Control&page=67", "query": { "intervention": "Safety Control", "page": 67 }, "page_size": 10 }, "pagination": { "page": 67, "page_size": 10, "total_count": 14141, "total_pages": 1415, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Control&page=68&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Control&page=66&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-09T01:36:48.254Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01436071", "title": "Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Fluticasone furoate 50mcg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 248, "start_date": "2011-09", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2017-01-11", "last_synced_at": "2026-11-09T01:36:48.254Z", "location_count": 10, "location_summary": "Long Beach, California • Los Angeles, California • Newport Beach, California + 7 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Albany", "state": "Georgia" }, { "city": "Columbia", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01436071" }, { "nct_id": "NCT04130802", "title": "OCS-01 in Treating Inflammation and Pain in Post-cataract Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Inflammation Corneal", "Pain, Postoperative" ], "interventions": [ { "name": "OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oculis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2019-09-27", "completion_date": "2020-01-31", "has_results": true, "last_update_posted_date": "2025-09-10", "last_synced_at": "2026-11-09T01:36:48.254Z", "location_count": 4, "location_summary": "Petaluma, California • Roseburg, Oregon • Houston, Texas + 1 more", "locations": [ { "city": "Petaluma", "state": "California" }, { "city": "Roseburg", "state": "Oregon" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04130802" }, { "nct_id": "NCT01433757", "title": "Ampicillin for DYT-1 Dystonia Motor Symptoms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "DYT-1", "Dystonia" ], "interventions": [ { "name": "Ampicillin", "type": "DRUG" }, { "name": "Sugar pill", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "7 Years to 80 Years" }, "enrollment_count": 2, "start_date": "2011-09", "completion_date": "2017-06", "has_results": false, "last_update_posted_date": "2017-07-05", "last_synced_at": "2026-11-09T01:36:48.254Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01433757" }, { "nct_id": "NCT07038200", "title": "A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Facioscapulohumeral Muscular Dystrophy", "FSHD", "FSHD - Facioscapulohumeral Muscular Dystrophy", "FSHD1", "FSHD2", "Fascioscapulohumeral Muscular Dystrophy", "Fascioscapulohumeral Muscular Dystrophy Type 1", "Fascioscapulohumeral Muscular Dystrophy Type 2", "Facioscapulohumeral Muscular Dystrophy 1", "Facioscapulohumeral Dystrophy", "Facio-Scapulo-Humeral Dystrophy", "Facioscapulohumeral Muscular Dystrophy 2", "Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1)", "FSH Muscular Dystrophy", "Landouzy Dejerine Dystrophy", "Landouzy-Dejerine Muscular Dystrophy", "Landouzy-Dejerine Syndrome" ], "interventions": [ { "name": "AOC-1020", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avidity Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "16 Years to 70 Years" }, "enrollment_count": 200, "start_date": "2025-06-10", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-11-09T01:36:48.254Z", "location_count": 14, "location_summary": "Orange, California • Palo Alto, California • Denver, Colorado + 11 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT07038200" }, { "nct_id": "NCT03217136", "title": "MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Complicated Intra-Abdominal Infection" ], "interventions": [ { "name": "Ceftolozane/Tazobactam", "type": "DRUG" }, { "name": "Metronidazole", "type": "DRUG" }, { "name": "Meropenem", "type": "DRUG" }, { "name": "Placebo for Metronidazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Days", "maximum_age": "17 Years", "sex": "ALL", "summary": "7 Days to 17 Years" }, "enrollment_count": 94, "start_date": "2018-04-03", "completion_date": "2020-03-16", "has_results": true, "last_update_posted_date": "2023-05-06", "last_synced_at": "2026-11-09T01:36:48.254Z", "location_count": 9, "location_summary": "Los Angeles, California • Orange, California • San Diego, California + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03217136" }, { "nct_id": "NCT06951711", "title": "A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bipolar Disorder Type I With Mania or Mania With Mixed Features" ], "interventions": [ { "name": "KarXT", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 274, "start_date": "2025-06-13", "completion_date": "2026-11-02", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-11-09T01:36:48.254Z", "location_count": 28, "location_summary": "Little Rock, Arkansas • Rogers, Arkansas • Culver City, California + 23 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Culver City", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06951711" }, { "nct_id": "NCT03733444", "title": "A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Idiopathic Pulmonary Fibrosis" ], "interventions": [ { "name": "GLPG1690", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lakefront Biotherapeutics NV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 781, "start_date": "2018-11-05", "completion_date": "2021-03-30", "has_results": true, "last_update_posted_date": "2022-07-29", "last_synced_at": "2026-11-09T01:36:48.254Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03733444" }, { "nct_id": "NCT07424144", "title": "An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Rhinosinusitis With Nasal Polyps" ], "interventions": [ { "name": "Itepekimab (SAR440340)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2026-03-12", "completion_date": "2027-02-17", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-11-09T01:36:48.254Z", "location_count": 3, "location_summary": "La Mesa, California • Oklahoma City, Oklahoma • Fort Worth, Texas", "locations": [ { "city": "La Mesa", "state": "California" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Fort Worth", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07424144" }, { "nct_id": "NCT02956122", "title": "A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Graft Versus Host Disease" ], "interventions": [ { "name": "GLASSIA", "type": "BIOLOGICAL" }, { "name": "methylprednisolone or equivalent steroid", "type": "DRUG" }, { "name": "Albumin", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Baxalta now part of Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2017-04-26", "completion_date": "2018-05-03", "has_results": true, "last_update_posted_date": "2021-01-13", "last_synced_at": "2026-11-09T01:36:48.254Z", "location_count": 1, "location_summary": "Augusta, Georgia", "locations": [ { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02956122" }, { "nct_id": "NCT05163522", "title": "First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "VH4004280", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 73, "start_date": "2021-12-13", "completion_date": "2023-06-21", "has_results": true, "last_update_posted_date": "2025-07-30", "last_synced_at": "2026-11-09T01:36:48.254Z", "location_count": 1, "location_summary": "Las Vegas, Nevada", "locations": [ { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT05163522" } ] }